The global burden of lung cancer: current status and future trends

A Leiter, RR Veluswamy, JP Wisnivesky - Nature reviews Clinical …, 2023‏ - nature.com
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer
incidence and mortality rates differ substantially across the world, reflecting varying patterns …

Targeting KRAS in cancer

A Singhal, BT Li, EM O'Reilly - Nature medicine, 2024‏ - nature.com
RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal

I De Bruijn, R Kundra, B Mastrogiacomo, TN Tran… - Cancer …, 2023‏ - aacrjournals.org
International cancer registries make real-world genomic and clinical data available, but their
joint analysis remains a challenge. AACR Project GENIE, an international cancer registry …

The pentose phosphate pathway in health and disease

T TeSlaa, M Ralser, J Fan, JD Rabinowitz - Nature metabolism, 2023‏ - nature.com
The pentose phosphate pathway (PPP) is a glucose-oxidizing pathway that runs in parallel
to upper glycolysis to produce ribose 5-phosphate and nicotinamide adenine dinucleotide …

The current state of the art and future trends in RAS-targeted cancer therapies

SR Punekar, V Velcheti, BG Neel… - Nature reviews Clinical …, 2022‏ - nature.com
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Quantifying the expanding landscape of clinical actionability for patients with cancer

SP Suehnholz, MH Nissan, H Zhang, R Kundra… - Cancer …, 2024‏ - aacrjournals.org
There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

CJ Schulze, KJ Seamon, Y Zhao, YC Yang, J Cregg… - Science, 2023‏ - science.org
The discovery of small-molecule inhibitors requires suitable binding pockets on protein
surfaces. Proteins that lack this feature are considered undruggable and require innovative …

Therapeutic landscape and future direction of metastatic colorectal cancer

H Bando, A Ohtsu, T Yoshino - Nature Reviews Gastroenterology & …, 2023‏ - nature.com
In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Harnessing multimodal data integration to advance precision oncology

KM Boehm, P Khosravi, R Vanguri, J Gao… - Nature Reviews …, 2022‏ - nature.com
Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

[HTML][HTML] Role of FGFR3 in bladder cancer: Treatment landscape and future challenges

CM Ascione, F Napolitano, D Esposito… - Cancer Treatment …, 2023‏ - Elsevier
Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …